SML0700
FTY720
≥98% (HPLC), powder, sphingosine 1-phosphate receptor modulator
别名:
2-氨基-2- [2-（4-辛基-苯基）-乙基]-丙烷-1,3-二醇 盐酸盐, 芬戈莫德 盐酸盐
产品名称
FTY720, ≥98% (HPLC)
SMILES string
Cl.NC(CO)(CO)CCc1ccc(cc1)CCCCCCCC
InChI
1S/C19H33NO2.ClH/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22;/h9-12,21-22H,2-8,13-16,20H2,1H3;1H
InChI key
SWZTYAVBMYWFGS-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
water: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
相关类别
Application
FTY720已被用作一种免疫调节剂，可用于研究其对P19C5干细胞的体外原肠胚模型的影响。它还可用于确定其延长角膜移植存活的功效。通过使用5-溴-2-脱氧尿苷掺入测定、神经球形成试验和蛋白质印迹分析，FTY720已被用于研究其对培养的胚胎海马神经干细胞（NSCs）的增殖和分化的影响。
Biochem/physiol Actions
FTY720是一种免疫调节药物以及1-磷酸鞘氨醇（S1P）受体的调节剂。 鞘氨醇激酶对FTY270的磷酸化可导致S1P1R的内化，从而螯合淋巴结中的淋巴细胞，阻止它们参与自身免疫反应。 临床上，它已被批准用于治疗多发性硬化症（MS）。研究显示其可通过抑制S1PR阻断和逆转紫杉醇诱导的化疗诱导的周围神经病变（CIPN），并可抑制小鼠脑海马中组蛋白脱乙酰酶的活性，从而调节记忆。
FTY720是一种免疫调节药物，可作为鞘氨醇-1-磷酸（S1P）受体的调节剂。
signalword
Warning
hcodes
pcodes
Hazard Classifications
STOT RE 2
target_organs
Immune system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
Linda Rolf et al.
Neurology, 82(11), 1008-1009 (2014-02-14)
Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis.
Groh J, et al.
Molecular Therapy, 25(8), 1889-1899 (2017)
Hao-Dong Li et al.
JCI insight, 5(14) (2020-07-24)
Cancer is instigated by mutator phenotypes, including deficient mismatch repair and p53-associated chromosomal instability. More recently, a distinct class of cancers was identified with unusually high mutational loads due to heterozygous amino acid substitutions (most commonly P286R) in the proofreading
Nicola Ivan Lorè et al.
mBio, 11(2) (2020-03-05)
Human genetics influence a range of pathological and clinical phenotypes in respiratory infections; however, the contributions of disease modifiers remain underappreciated. We exploited the Collaborative Cross (CC) mouse genetic-reference population to map genetic modifiers that affect the severity of Pseudomonas
M Mehling et al.
Neurology, 76(8 Suppl 3), S20-S27 (2011-02-26)
The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)).
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持